Drugs / VCL-HB01
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02030301 | Dec 2013 → Jun 2015 | genital herpes simplex type 2 infectious disorder | Vical | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02837575 | Sep 2016 → Apr 2018 | genital herpes | Vical | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VCL-HB01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02837575 ↗ |
| Modality | Vaccine | “Plasmid DNA vaccine encoding two HSV-2 proteins; formulated with Vaxfectin®” NCT02030301 ↗ |
| Route | Intramuscular | “by intramuscular injection” NCT02030301 ↗ |